



Bubs Australia Limited
ACN 060 094 742
23-29 Nina Link, Dandenong South
VIC 3175 Australia

1800 2827 2878 (1800 BUBS AUST)
info@bubsaustralia.com

ASX ANNOUNCEMENT

Permanent FDA Authorisation Webinar Notification

8 September 2026, Melbourne: Bubs Australia Limited (ASX: BUB) ("**Bubs**" or "**the Company**") will host a webinar to discuss its recent receipt of permanent regulatory authorisation from the United States Food and Drug Administration (**FDA**), as announced on 7 September 2026.

Joe Coote (Chief Executive Officer), Chris Rowe (Chief Financial Officer) and Jasmin Manner (President – USA) will host the webinar at 11:00am (AEST) on Thursday, 10 September 2026.

To participate, please register via the following link:

Webinar: <https://us02web.zoom.us/j/89619722879>

This release is approved by the Company Secretary.

END

Shareholder enquiries

Adrian Mulcahy, Automic

adrian.mulcahy@automic.group.com.au

T: +61 438 630 422

investors@bubsaustralia.com

Media enquiries

Sophie Hulme

sophie.hulme@bubsaustralia.com

T: +61 423 114 169

ABOUT BUBS AUSTRALIA LIMITED (ASX: BUB)

Bubs Australia (ASX: BUB) is a leading infant nutrition company committed to providing premium-quality products that support the health and wellbeing of babies worldwide. Founded in 2006, Bubs has built a reputation for innovation and excellence, offering a range of organic and specialty infant formulas, including goat milk and grass-fed options. With a strong presence in Australia, the United States and growing international markets, including China, Bubs is dedicated to delivering trusted nutrition backed by rigorous quality standards. For more information, visit www.bubsaustralia.com or our social media channels.

Consumer Website:

bubsaustralia.com

Investor Centre:

investor.bubsaustralia.com
